1. Department of Radiation Oncology, Fourth Hospital of Hebei Medical University, Shijiazhuang, Hebei, China. 2. Department of Colorectal Surgery, Fourth Hospital of Hebei Medical University, Shijiazhuang, Hebei, China. 3. Department of Medical Imaging, Second Hospital of Hebei Medical University, Shijiazhuang, Hebei, China. #Co-first authors with equal contributions to this work.
✉ Corresponding author: Guiying Wang, PhD, The Fourth Hospital of Hebei Medical University, Shijiazhuang, Hebei 050011, China. Tel: +86-311-86095361; E-mail: WFP1978edu.cn.
Citation:
Wu F, Zhou C, Wu B, Zhang X, Wang K, Wang J, Xiao L, Wang G. Adding Adjuvants to Fluoropyrimidine-based Neoadjuvant Chemoradiotherapy for Locally Advanced Rectal Cancer: An Option Worthy of Serious Consideration. J Cancer 2021; 12(2):417-427. doi:10.7150/jca.48337. https://www.jcancer.org/v12p0417.htm
The application of fluoropyrimidine-based neoadjuvant chemoradiotherapy (Fu-nCRT) of locally advanced rectal cancer (LARC) has become a common therapeutic regimen. In order to improve the efficacy and enable more patients to benefit from this treatment, an accumulation of studies have been carried out on the auxiliary use of other drugs with Fu-nCRT. However, due to specific challenges and the potential opportunities that coexist in this field, a more reasonable approach to the mode of treatment remains to be explored. In this review, we have summarized the results of the studies on the combination of Fu-nCRT with cytotoxic drugs, anti-tumor angiogenesis, and anti-EGFR agents, as well as the status of the application of immune checkpoint inhibitors in the neoadjuvant therapy of LARC patients.
Wu, F., Zhou, C., Wu, B., Zhang, X., Wang, K., Wang, J., Xiao, L., Wang, G. (2021). Adding Adjuvants to Fluoropyrimidine-based Neoadjuvant Chemoradiotherapy for Locally Advanced Rectal Cancer: An Option Worthy of Serious Consideration. Journal of Cancer, 12(2), 417-427. https://doi.org/10.7150/jca.48337.
ACS
Wu, F.; Zhou, C.; Wu, B.; Zhang, X.; Wang, K.; Wang, J.; Xiao, L.; Wang, G. Adding Adjuvants to Fluoropyrimidine-based Neoadjuvant Chemoradiotherapy for Locally Advanced Rectal Cancer: An Option Worthy of Serious Consideration. J. Cancer 2021, 12 (2), 417-427. DOI: 10.7150/jca.48337.
NLM
Wu F, Zhou C, Wu B, Zhang X, Wang K, Wang J, Xiao L, Wang G. Adding Adjuvants to Fluoropyrimidine-based Neoadjuvant Chemoradiotherapy for Locally Advanced Rectal Cancer: An Option Worthy of Serious Consideration. J Cancer 2021; 12(2):417-427. doi:10.7150/jca.48337. https://www.jcancer.org/v12p0417.htm
CSE
Wu F, Zhou C, Wu B, Zhang X, Wang K, Wang J, Xiao L, Wang G. 2021. Adding Adjuvants to Fluoropyrimidine-based Neoadjuvant Chemoradiotherapy for Locally Advanced Rectal Cancer: An Option Worthy of Serious Consideration. J Cancer. 12(2):417-427.
This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/). See http://ivyspring.com/terms for full terms and conditions.